Specifications for Starting Materials, Intermediates and Finished Products

Nirav R.Soni*
Dept. of Quality Assurance (QA)
*A-one Pharmacy college, Enasan
nirav_soni@yahoo.com

ABSTRACT

The specifications are to assure that each unit has the value of drug claimed on the label, that all the drug in each unit is out there for whole use, that the drug steady within the formula in its certain final container for their expected shelf life and it’s having no toxic overseas substance. It’s greatly utilized in pharmaceutical enterprise and utilized by using wellness sector and support best which is finished via GMP, GLP and GCP and other organization including Pharmaceutical Quality System (PQS), Quality Risk Management (QRM) and Quality by Design (QbD).

Keywords: Regulatory control steps, Development specifications, Importance specification of various dosage forms.

INTRODUCTION

Specifications for APIs and pharmaceutical drug products, both chemical components and biologics, are vital used for product quality and patient protection. The goals of specification arrangements are (1) to identify appropriate and safe limits or quantitative ranges during clinical development and (2) to give specifications for the product to enter the market. One of the most difficult challenges in establishing and consequently giving specifications is achieving the appropriate balance among all factors including human safety health and their efficacy, scientific proven data, analytical variability, process knowledge and capability, regulatory requirements, and business issues. It is most important for a pharmaceutical company to have an effective and regulatory compliant approach to setting some requirements that can analyzed by both EMA and FDA requirements and expectations. At each stage of drug development, from Phase 1 clinical trials via commercialization, the basic question needs to be addressed: ‘What is absolutely obligatory for the assigned specification to be doing well in getting the chemical drug/biologic components via clinical trials and into the worldwide market, but without impacting patient safety or creating delays in the programme?’ of equal significant value is the require to describe which quality attributes do not need an assigned specification. Regulatory obedient deficiencies in take off some specifications have resulted in clinical holds and market approval delays.

This course will support the attendee to establish specifications meeting global regulatory requirements and expectations. Participants may also come to be strong in justification of specifications.

The term starting material has been absorbed where; regulatory change control and current good manufacturing practice are introduced into the synthesis of a various drug components. There is a drug components synthesis is shown in Figure 1. This conventional scheme depicts four regulatory steps and quite a lot of excellent manipulate points (specifications).

Steps 1–4 includes a covalent bond formation. The various regulatory steps are disclosed in the Marketing Authorization Application and necessitate regulatory approval for changes. “Red Boxes” have the greatest regulatory importance. Materials in “bold text” are generally given a comprehensive and robust specification. “Orange Boxes” which are synthetic intermediates and can be isolated or

How to cite this article: Soni N; Specifications for Starting Materials, Intermediates and Finished Products; PharmaTutor; 2016; 4(11); 21-26
remain in situ but are controlled using a more limited specification. (image source/getty images). \[1,7,18\]

Figure 1: Schematic chart of regulatory drug substance synthesis.

Using a science and risk based framework, this article reviews the various regulatory guidelines in the EMEA, USFDA and MHLW. In addition, the authors address the International Conference on Harmonization (ICH) guidelines that recently impact the selection of starting materials for new drug components or substances for worldwide registration. The discussion takes in the initial publication with the introduction of various guidelines since ICH Q8 and Q9 “Pharmaceutical Development”, “QRM” respectively, and the withdrawal of FDA’s BACPAC I and drug substance ICH guidance. \[2-7,16\]

DEVELOPMENT OF SPECIFICATIONS:- Historical batch records of various pilot and production batches are usually the best source for establishment of meaningful specification and their development. Long run experience of production of same product always modifies specification required for finished product. A person authorized by Q.C. manager is responsible for approval of specifications. See below Table 1. \[9-15\]

Table 1: Criteria for Batch development.

<table>
<thead>
<tr>
<th>Drug substance</th>
<th>XYZ</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proposed Potency limits</td>
<td>93-107%</td>
</tr>
<tr>
<td>Method</td>
<td>Chloroform ext. followed by UV spectra</td>
</tr>
<tr>
<td>Reproducibility</td>
<td>+/-2%</td>
</tr>
<tr>
<td>Batch Record</td>
<td>99.3, 98.4, 103.4, 97.9, 101.3, 98.9, 101.8, 99.7, 98.6, 100.4</td>
</tr>
<tr>
<td>Acceptable limits</td>
<td>95-105%</td>
</tr>
<tr>
<td>House limit</td>
<td>96-104%</td>
</tr>
</tbody>
</table>

FOLLOWING OBJECTIVES SHOULD BE COVERED IN DEVELOPMENT OF SPECIFICATION. \[18-22\]

1. To ascertain which physical, chemical and biological characteristics of dosage form are critical which are helpful and which are not particularly important but are useful.
2. To decide which dosage form characteristic shall be established as the criteria for evaluating routine production batches.
3. To establish the appropriate test methods for evaluating the selected criteria.
4. To determine the acceptable tolerance and limit for each of the dosage form characteristic.

STARTING MATERIALS \[23-29\]:- Any substance of defined quality used in the production of pharmaceutical product, but excluding the packaging materials. Bulk Pharmaceutical Chemicals

SPECIFICATIONS FOR STARTING MATERIALS \[24-26\]

(1) Generic and chemical name of the material.
(2) Trade name or product code established by manufacturer.
(3) Description
(4) Name of pharmacopoeia (if official in pharmacopoeia) in which monograph appears or name of various recognized book of standards or international non-proprietary name(inn).
(5) If not official in pharmacopoeia or any other book of standards, monograph to be employed for testing containing tests and limits for identity, their purity as well as physical and chemical characteristics microbiological standards (if any) and assay.
(6) Approved suppliers.
(7) Frequency of testing of stored material.
(8) Special precautions to be taken during storage including safety aspects.
(9) Date of issue of specification.
SPECIFICATIONS FOR THE DOCUMENTATION OF STARTING MATERIALS

(1) Designated name and internal code reference.
(2) The reference if any to pharmacopoeial monograph.
(3) Qualitative and quantitative requirements with acceptance limits.
(4) Packaging material should decide to some specification and compatible with material or chemical substances.
(5) Examined for defects and correctness of identity markings.
(6) Documents should state necessary frequency for further assaying each starting material, as determined by its stability.
(7) Specifications for starting materials are likely to identification, assay method or procedure, and other organic volatile impurities (limits for determined, undetermined, genotoxic and total identification). In other cases, these requirements are most supplemented with those for extra residual solvents, catalysts or heavy metals and chirality.

SPECIFICATIONS FOR THE INTERMEDIATE

Intermediate product is considered as one which is at any stage after dispensing of material and not got converted into packable bulk material. It should be accessible if these are bought or taken or if data obtained from intermediate products are used in the evaluation of the finished product. Some specification required like it should be kept under appropriate conditions. If purchased as such handled on receipt as though these are starting materials. [24]

SPECIFICATIONS FOR THE FINISHED PRODUCTS

Finished products are those products which are ready for final dispatch to market or distribution. [23]

SPECIFICATIONS :-It should be some specification of two separate sets of manufacture (at release) and at the end of t₀

* A list of common characteristics, particular standards, tests and limits for the given results for the finished product must be provided. Another is
* All analytical test procedures used must be described in enough description like biological and microbiological methods where; relevant to enable the procedures to be repeated if necessary. [26, 28]

The following control methods must be included in the specification [23-29]

(1) General characteristics of the pharmaceutical form like physicochemical properties
(2) Identification tests of the active substances;
(3) Quantitative identification of active substances.
(4) Unlike there is appropriate justification, the maximum acceptable deviation in the active ingredients content of the finished product shall not exceed +/-5% at the time of manufacture.
(5) Purity tests (breakable products, residual solvents or extra process related impurities, microbial contamination).
(6) Pharmaceutical tests, e.g. dissolution;
(7) The identification tests for coloring materials used and identification and assay of antimicrobial or some chemical preservatives with beneficial limits. The preservatives content limits of 90-110 percent at release are suitable without further justification except in special cases.
(8) All procedures need to be validated. Results of the validation, comments on the in-house tests and standards must be provided.
(9) If the final product is tested on the basis of a monograph procedure given in a pharmacopoeia, it is ample to provide a copy of the monograph together with any test methods referenced but it is not copied in the standard monograph provide details of any specifications additional to those in the pharmacopoeia. It provides the results of validation of the assay procedure or method for this formulation.
(10) For pharmacopoeial methods, provide data which shows that the method is applicable to this formulation. Results of batch analysis (including the date and place of manufacture, batch size and use of batch tested) must be presented. The batch analysis must involve the results seen for all specifications at release.

SPECIFICATIONS FOR DOCUMENTATION OF FINISHED PRODUCTS which include;

(a) Reference code and name
(b) Names of actives (e.g. INN)
(c) Formula
(d) Dosage form, package details
(e) Reference to sampling
(f) Qualitative and quantitative requirements and limits
(g) Storage conditions and precautions
(h) Shelf life

SPECIFICATIONS FOR FINISHED PRODUCTS ALSO INCLUDE:- (a) Generic name of product (b) Trade name if any (c) Dosage form and strength (d) Description including particulars such as colour, shape, dimensions, taste etc. (e) Physical properties such as weights or volumes (including limits) pH, viscosity, density, hardness, friability, disintegration time, dissolution time etc. (f) Name of pharmacopoeia or any other recognized book of standards in which its monograph appears, if not official, monograph to be employed for testing containing test for identity and purity, microbiological standards, if any biological tests, if any and assay; (f) Date of expiry. (g) Precautions during storage including safety aspects (h) Date of issue of specifications.

IMPORTANT SPECIFICATIONS FOR VARIOUS DOSAGE FORM

TABLET & CAPSULE:
A) Physical appearance - Size and Shape
B) Physical Tests - including various tests like Hardness, Disintegration test, Dissolution, Friability and Weight variation test
C) Identification, assay, related substance tests
D) Shelf-life determination (specially in new products)
E) Packaging & Labeling

I) Outer Carton
II) Small Pack
III) Strip Pack/Blister Pack
IV) Tin Pack/Bottle Pack
OINTMENT/CREAM:
A) Physical Appearance
B) Physical Test - including pH, Quantity determination, Foreign particle, Spreadability, Permeability,
C) Identification, Assay, Related Substance Tests
D) Expiry Determination
E) Packaging & Labeling

LIQUID PREPARATION
A) Physical Appearance - Color and odor of liquid and Visual inspection
B) Physical Tests - including Taste of liquid, pH, Volume, PSD/GSD (suspension), Type of emulsion, SVR (suspension), Re-dispersibility and Test of creaming (emulsion)
C) Identification, assay, related substance tests
D) Expiry determination
E) Packaging & Labeling

PARANTRAL PREPARATION
A) Physical Appearance - Color & clarity of liquid
B) Physical tests - pH, Volume, Leak test, Syringibility
C) Identification, Assay, Related Substance Tests
D) Special Requirements like Pyrogen testing and Sterility testing
E) Expiry Determination
F) Packaging & Labelling

F1) Outer Carton
F2) Small Pack
F3) Vials
F4) Ampoules
SPECIFICATIONS FOR STORAGE OF PHARMACEUTICAL FINISHED PRODUCT²⁷⁻²⁹

(1) Finished product should be held in quarantine until their final release, after which they should not be stored as unsalable stock under conditions established by the manufacturer.

(2) A separate area should be provided for the storage of the finished product.

(3) Finished product may be stored according to their dosage form.

(4) These storage areas should have adequate height and ventilation, adequate storage equipment like plant forms plastic and wooden, racks etc. nearby, to finished product area, an assembling and packaging area may be provided to execute sales orders, if space permits.

CONCLUSION

In the conclusion, every dosage forms having particular identity and test should be performed by analytical test including physical, chemical and biological for some standard and specification. It covers some criteria and gives quality of product not only but enhances the quality and characteristics for earlier stage to finished product even packaging. It has required for globalization and preparation of various novel dosage forms.

REFERENCES

3. ICH Q8 Pharmaceutical Development; Geneva, Switzerland; [cited 2006 May].
4. ICH Q9 Quality Risk Management (Geneva, Switzerland, [cited 2006 June].
7. ICH Q7 Good Manufacturing Guide For Active Pharmaceutical Ingredients, Geneva, Switzerland, [cited 2001 August].
9. FDA, Guidance for Industry: Changes to an Approved NDA or ANDA, Rev. 1 Rockville, MD, [cited 2004 Apr].
11. EU Guidelines to Good Manufacturing Practice, Medicinal Products for Human and Veterinary Use, Part II, Basic Requirements for Active Substances used as Starting Materials (Brussels, Belgium, Oct. 2005).
13. MHLW, Pharmaceutical and Food Safety Bureau, Guidelines on Mentions in Manufacturing / Marketing Approval Application Dossiers for Pharmaceuticals and Others Based on Revised Pharmaceutical Affairs Law, PFSB/ELD 020001 Tokyo, Japan, [cited 2005 Feb 10].
15. ICH Q3A R2 Impurities in New Drug Substances Geneva, Switzerland [cited 2006 June].
20. Code of Federal Regulations, Title 21, Food and Drugs, Volume 3, Chapter 1, Subpart B: Food Additive Safety, Section 170.39: Threshold of Regulation for Substances Used in Food-Contact Articles ; General Services Administration, Revised [cited 2007 Apr 1].